157 related articles for article (PubMed ID: 38196018)
1. Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and immunotherapy outcomes prediction.
Xu J; Chen H; Fan W; Qiu M; Feng J
J Cancer Res Clin Oncol; 2024 Jan; 150(1):7. PubMed ID: 38196018
[TBL] [Abstract][Full Text] [Related]
2. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.
Wang S; Meng F; Li M; Bao H; Chen X; Zhu M; Liu R; Xu X; Yang S; Wu X; Shao Y; Xu L; Yin R
Am J Respir Crit Care Med; 2023 May; 207(9):1203-1213. PubMed ID: 36346614
[No Abstract] [Full Text] [Related]
3. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.
Guo W; Chen X; Liu R; Liang N; Ma Q; Bao H; Xu X; Wu X; Yang S; Shao Y; Tan F; Xue Q; Gao S; He J
EBioMedicine; 2022 Jul; 81():104131. PubMed ID: 35780566
[TBL] [Abstract][Full Text] [Related]
4. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
[TBL] [Abstract][Full Text] [Related]
5. Utility of Circulating Free DNA Fragmentomics in the Prediction of Pathological Response after Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
Wang Y; Fan X; Bao H; Xia F; Wan J; Shen L; Wang Y; Zhang H; Wei Y; Wu X; Shao Y; Li X; Xu Y; Cai S; Zhang Z
Clin Chem; 2023 Jan; 69(1):88-99. PubMed ID: 36308331
[TBL] [Abstract][Full Text] [Related]
6. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
[TBL] [Abstract][Full Text] [Related]
7. Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics.
Shi X; Guo S; Duan Q; Zhang W; Gao S; Jing W; Jiang G; Kong X; Li P; Li Y; Teng C; Xu X; Chen S; Nian B; Li Z; Zhong C; Yang X; Zhu G; Du Y; Zhang D; Jin G
J Exp Clin Cancer Res; 2024 May; 43(1):145. PubMed ID: 38750539
[TBL] [Abstract][Full Text] [Related]
8. Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma.
Luo B; Ma F; Liu H; Hu J; Rao L; Liu C; Jiang Y; Kuangzeng S; Lin X; Wang C; Lei Y; Si Z; Chen G; Zhou N; Liang C; Jiang F; Liu F; Dai W; Liu W; Gao Y; Li Z; Li X; Zhou G; Li B; Zhang Z; Nian W; Luo L; Liu X
BMC Med; 2022 Jan; 20(1):8. PubMed ID: 35027051
[TBL] [Abstract][Full Text] [Related]
9. Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids.
Kim J; Hong SP; Lee S; Lee W; Lee D; Kim R; Park YJ; Moon S; Park K; Cha B; Kim JI
Hum Genomics; 2023 Oct; 17(1):96. PubMed ID: 37898819
[TBL] [Abstract][Full Text] [Related]
10. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.
Lee KWC; Li MSC; Gai W; Lau YM; Chan AKC; Chan OSH; Lee CK; Yeung RMW; Fung SYH; Cheung WF; Chan VW; Leung L; Kam KNP; Mok TSK
JAMA Oncol; 2023 Feb; 9(2):261-265. PubMed ID: 36580285
[TBL] [Abstract][Full Text] [Related]
11. Testing the generalizability of cfDNA fragmentomic features across different studies for cancer early detection.
Su S; Xuan Y; Fan X; Bao H; Tang H; Lv X; Ren W; Chen F; Shao Y; Wang T; Wang L
Genomics; 2023 Jul; 115(4):110662. PubMed ID: 37270068
[TBL] [Abstract][Full Text] [Related]
12. Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma.
Ma X; Chen Y; Tang W; Bao H; Mo S; Liu R; Wu S; Bao H; Li Y; Zhang L; Wu X; Cai S; Shao Y; Liu F; Peng J
J Hematol Oncol; 2021 Oct; 14(1):175. PubMed ID: 34702327
[TBL] [Abstract][Full Text] [Related]
13. Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer.
Lu D; Wu X; Wu W; Wu S; Li H; Zhang Y; Yan X; Zhai J; Dong X; Feng S; Zhang X; Sun F; Wang S; Cai K
Cell Death Dis; 2023 Dec; 14(12):843. PubMed ID: 38114477
[TBL] [Abstract][Full Text] [Related]
14. Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection.
Bao H; Wang Z; Ma X; Guo W; Zhang X; Tang W; Chen X; Wang X; Chen Y; Mo S; Liang N; Ma Q; Wu S; Xu X; Chang S; Wei Y; Zhang X; Bao H; Liu R; Yang S; Jiang Y; Wu X; Li Y; Zhang L; Tan F; Xue Q; Liu F; Cai S; Gao S; Peng J; Zhou J; Shao Y
Mol Cancer; 2022 Jun; 21(1):129. PubMed ID: 35690859
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Single Molecule, Real-Time Sequencing and Nanopore Sequencing for Analysis of the Size, End-Motif, and Tissue-of-Origin of Long Cell-Free DNA in Plasma.
Yu SCY; Deng J; Qiao R; Cheng SH; Peng W; Lau SL; Choy LYL; Leung TY; Wong J; Wong VW; Wong GLH; Jiang P; Chiu RWK; Chan KCA; Lo YMD
Clin Chem; 2023 Feb; 69(2):168-179. PubMed ID: 36322427
[TBL] [Abstract][Full Text] [Related]
16. Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancer.
Guler GD; Ning Y; Coruh C; Mognol GP; Phillips T; Nabiyouni M; Hazen K; Scott A; Volkmuth W; Levy S
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212123
[TBL] [Abstract][Full Text] [Related]
17. A method for early diagnosis of lung cancer from tumor originated DNA fragments using plasma cfDNA methylome and fragmentome profiles.
Kim YJ; Jeon H; Jeon S; Lee SH; Kim C; Ahn JH; Um H; Woo YJ; Jeong SH; Kim Y; Park HY; Oh HJ; Cho HJ; Bae JH; Kim JH; An S; Kang SB; Jho S; Biro O; Kis D; Kim BC; Kim Y; Kim JH; Kim BC; Bhak J; Oh IJ
Mol Cell Probes; 2022 Dec; 66():101873. PubMed ID: 36379302
[TBL] [Abstract][Full Text] [Related]
18. Can circulating cell free DNA be a promising marker in ovarian cancer? - a genome-scale profiling study in a single institution.
Zhou H; Zhang X; Liu Q; Yang J; Bai J; Yin M; Cao D; Zhang Q; Zheng L
J Ovarian Res; 2023 Jan; 16(1):11. PubMed ID: 36641505
[TBL] [Abstract][Full Text] [Related]
19. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
20. Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing.
Zhang H; Dong P; Guo S; Tao C; Chen W; Zhao W; Wang J; Cheung R; Villanueva A; Fan J; Ding H; Schrodi SJ; Zhang D; Zeng C
BMC Med; 2020 Aug; 18(1):200. PubMed ID: 32741373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
